Thats not what I'm stating.. Personally I dont think they would be able to come to a deal that both parties agree to.
How much would Amgen pay for licensing of one indication in one region? My guess is they would want a lot more use of Bisantrene (who wouldn't!), and RAC are not in the position they want to be in to be making that deal. That's all.
Ann: Race Strategic Update August 2023, page-592
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
-0.090(5.06%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.63 | $449.0K | 263.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2300 | $1.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 8176 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |